Published on
Last updated on
China Tightens Compliance Expectations for Online Prescription Drug Sales
On May 25, 2026, China’s National Medical Products Administration (NMPA) issued the “Compliance Guidelines for Online Retail Sales of Prescription Drugs” to regulate online prescription drug sales, strengthen drug safety oversight, and clarify compliance expectations for online pharmacies and third-party platforms.
The Guidelines signal a more detailed compliance framework for China’s online prescription drug ecosystem. For companies participating in online prescription drug sales, the key message is clear: prescription drug e-commerce must be managed as a regulated healthcare activity, not as ordinary consumer retail.
Why the Guidelines Matter
China’s online pharmaceutical retail market has expanded rapidly, but regulators continue to identify recurring compliance deficiencies.
According to the NMPA’s policy interpretation, routine inspections and regulatory monitoring have identified recurring compliance deficiencies, including:
- Illegal online prescription drug sales
- Sales without valid prescriptions
- Inadequate prescription review
- Incomplete compliance management systems
- Weak operating mechanisms and
- Insufficient understanding of compliance responsibilities among some platforms and online retailers
The Guidelines seek to address these risks by clarifying regulatory expectations across the entire online prescription drug sales process, creating a more demanding compliance environment for pharmacies, platforms, and their business partners.
Core Principle: Diagnosis First, Prescription Second, Drug Sale Third
Based on the principle of “diagnosis first, prescription second, and drug sale third,” online pharmacies and third-party platforms must design workflows and user interfaces that clearly distinguish among:
- Medical consultation
- Prescription issuance
- Prescription review
- Drug retail sales
User interfaces and ordering workflows should not encourage consumers to select or purchase prescription drugs before appropriate medical and pharmacist oversight has occurred.
In practice, companies may need to reassess ordering processes, prescription-upload functions, platform design, and arrangements with internet healthcare providers to ensure compliance with this principle.
Licensed Pharmacists Are the Key Compliance Gatekeepers
The Guidelines make clear that prescription review must be performed by licensed pharmacists. Prescription review by artificial intelligence systems or personnel without appropriate qualifications is expressly prohibited.
Licensed pharmacists are responsible for:
- Drug quality management
- Prescription review and dispensing
- Rational medication guidance
- Collection and reporting of adverse drug reaction information
The Guidelines also require online pharmacies to employ sufficient numbers of licensed pharmacists based on business scope, product portfolio, transaction volume, prescription-review workload, and quality-management requirements.
For businesses relying on automated processes, the message is straightforward: technology may support operations, but it cannot replace pharmacist accountability. Licensed pharmacists must remain responsible for prescription review and related decision-making.
Product Pages and Digital Marketing Face Stricter Controls
The Guidelines impose detailed requirements on prescription drug information displays.
Before prescription review is completed, online sellers and platforms must not display or provide:
- Package inserts
- Indications
- Therapeutic functions
- Dosage and administration information
Prescription drug packaging, labels, and similar information also may not appear on third-party platform homepages, healthcare category homepages, or merchant storefront homepages.
Product listings and product pages must clearly distinguish prescription drugs from OTC medicines. Prescription drug pages must display prominent warnings, such as: “Prescription drugs must be purchased and used with a valid prescription under the guidance of a pharmacist.”
Medicines containing substances listed under anti-doping regulations must also carry warnings such as: “Athletes should use with caution.”
These requirements may necessitate changes to product pages, search results, category pages, app interfaces, and marketplace storefronts. Pharmaceutical manufacturers should also assess whether distributors, pharmacy partners, and platforms are using brand materials in ways that could create advertising or display-related compliance risks.
Sales Promotions Face Greater Restrictions
The Guidelines directly target sales practices that could encourage excessive or irrational medication use.
The Guidelines prohibit or discourage practices that may encuorage excessive or iraational medication use, including:
- Prize campaigns involving prescription drugs
- Buy-one-get-one offers
- Sales through redemption cards or verification codes
- Bundling prescription drugs with other products or medicines
- Marketing-oriented short videos
- Livestream promotions
- Private-domain sales channels
Pharmaceutical companies should review channel policies, distributor agreements, and e-commerce marketing practices to ensure that prescription drug sales are not driven by consumer-retail tactics.
Expanded Responsibilities for Third-Party Platforms
Third-party platforms receive particular attention because they control marketplace access, product visibility, transaction architecture, and merchant oversight.
The Guidelines require or encourage platforms to:
- Establish pharmaceutical quality management organizations and systems
- Employ pharmaceutical professionals responsible for drug safety management
- Monitor prescription circulation and prescription review processes
- Verify merchant qualifications
- Maintain prescription drug retailer registration files
- Review merchant qualifications at least once every six months
- Assess legal risks linked to external display, linking, or redirection services
- Verify qualifications of electronic prescription providers
- Detect and block fraudulent prescriptions and AI-generated prescriptions
These measures reflect the NMPA’s growing focus on preventing forged, recycled, irregular, or ai-generated prescriptions from entering the dispensing process.
Enhanced Controls for Abuse Risks, Minors, and Unusual Purchasing Patterns
The Guidelines call for stronger risk monitoring, especially for medicines that may present misuse or abuse risks.
Platforms are encouraged to monitor abnormal sales of:
- Medicines containing substances listed in anti-doping catalogues
- Compound preparations containing psychotropic substances
- Other medicines with abuse potential
Platforms should also establish controls that block transactions when purchases exceed reasonable usage quantities or when the same account repeatedly purchases excessive amounts.
Additional safeguards apply when prescription review indicates that the patient is a minor. In such cases, pharmacies must:
- Inform the purchaser that guardian consent is required
- Recommend pharmacist guidance
- Warn of medication safety risks
- Intercept the transaction when necessary
These requirements may drive greater investment in transaction monitoring, account-level risk screening, and escalation procedures for higher-risk purchases.
Traceability and Online-Offline Consistency Will Be Enforcement Priorities
Online pharmacies must verify drug traceability codes, maintain prescription and pharmaceutical-service records, distinguish online and offline sales records, and ensure that transaction data remains authentic, accurate, complete, and traceable.
The NMPA has also emphasized integrated online and offline supervision. Online drug retailers must be licensed offline businesses operating within approved business scopes and methods.
Regulators are expected to focus on operators whose shipping addresses differ from those listed in their business permits. They will also scrutinize inconsistencies between products sold online and those sold offline to prevent unlawful substitution or misrepresentation.
This creates practical risk for companies using complex fulfillment models, third-party warehouses, or multi-region distribution arrangements.
What Pharmaceutical Companies Should Do Next
Although the Guidelines primarily regulate online pharmacies and third-party platforms, they increase channel oversight and compliance exposure for pharmaceutical manufacturers whose products are sold and promoted through online channels.
In this context, pharmaceutical manufacturers should focus on three priorities:
#1. Channel Oversight
- Reviewing online channel governance strategies
- Monitoring compliance among distributors, pharmacy partners, and other third parties
- Strengthening contractual and compliance oversight of online sales and promotional activities
#2. Marketing and Higher-Risk Products
- Reviewing digital marketing materials and promotional practices
- Assessing how brand materials are used by online partners
- Evaluating products that may present misuse or abuse risks
#3. Internal Governance
- Integrating online-channel risks into compliance and quality management systems
- Establishing clear oversight and escalation procedures
- Monitoring regulatory developments and enforcement trends affecting online prescription drug sales
Final Thoughts
The NMPA’s new Guidelines are drawing a clear line: online prescription drug sales in China are to be regulated as healthcare delivery, not treated as standard e-commerce.
The key compliance question is no longer simply whether companies are licensed, but whether end-to-end online prescription drug systems are appropriately controlled — from prescribing and pharmacist review to platform governance and transaction execution. While execution often sits with platforms and distributors, pharmaceutical manufacturers should maintain appropriate oversight of how their products are promoted, accessed, and dispensed through these channels.
Against this backdrop, Cisema supports pharmaceutical companies, online healthcare businesses, and platform operators with regulatory strategy, compliance assessments, quality-system support, and market-entry planning across China and Asia.
For support in assessing and strengthening your online prescription drug compliance framework, contact Cisema today.
Further Information
References
Related News
China Revises Drug Clinical Trial GCP to Align with ICH E6(R3)
New rules strengthen data governance and raise sponsor oversight duties from September 2026.
Taiwan Proposes New Online Drug Enforcement Obligations Under Pharmaceutical Affairs Act
New rules expand platform accountability and regulatory oversight, reshaping how pharmaceutical products are promoted, sold, and controlled online.
NMPA Releases Guideline on Appropriate Pharmaceutical Packaging Sizes to Reduce Drug Waste & Over-Packaging
New NMPA packaging size guidance encourages drug applicants to align pack sizes with clinical use, patient needs, and sustainability goals.